By Fineline Cube 
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd announced this week a strategic partnership with compatriot firm Future Biotechnology. The collaboration aims to integrate their technological and service strengths to achieve deeper expansion in the viral vector field.
Collaboration Details
The partnership will create complementary resources to offer clients more comprehensive, efficient, standardized, and professional viral vector CRO and CDMO services. This move is expected to significantly advance the development of gene and cell therapy (GCT) industries.
Future Bio’s Expertise
Future Biotechnology specializes in the research and clinical translation of gene delivery vector products. The company has rapidly modified over 10 types of viral vectors using its Viral Matrix Platform technology.
Porton Bio’s Capabilities
Suzhou Porton Biologics Ltd boasts an end-to-end viral vector CDMO platform. It is capable of providing Good Manufacturing Practice (GMP) production services for viral vectors across all stages, from Investigator-Initiated Trials (IIT) and Investigational New Drug (IND) applications to clinical and commercial phases.
Scope of Collaboration
The collaboration will leverage each company’s strengths in viral delivery technologies, including adenovirus, lentivirus, adeno-associated virus, and oncolytic virus. The partnership covers innovative vector applications in basic research, cell therapy, gene therapy, vaccine development, and clinical/commercial promotion.-Fineline Info & Tech